HBM Healthcare Investments Reports Balanced Financial Performance for 2023/2024

HBM Healthcare Investments AG disclosed a slight annual loss of CHF 1 million in its 2023/2024 financial year. The company's net asset value per share increased by 0.3% following share buybacks, despite a 6.0% decline in share price.

The portfolio showed mixed results with certain biotech investments like Y-mAbs Therapeutics and Biohaven performing well, while others such as Cathay Biotech faced significant declines. Notably, Cathay Biotech's share price reduction resulted in a CHF 98 million loss, although the company's fundamental outlook remains strong.

Global market conditions were mixed; recovery in the US and European biotech sectors contrasted with downturns in China. Currency fluctuations, particularly against the Swiss Franc, negatively impacted overall financial results by about 2.5%.

While public holdings added CHF 69 million in value, private investments saw a net decrease of CHF 60 million, affected by negative revaluations in certain companies. However, strategic new investments were made in promising sectors such as immune disorder treatments and siRNA technologies.

HBM Healthcare maintains a balanced asset allocation and has proposed an unchanged par value repayment of CHF 7.50 per share. Looking ahead, despite a challenging macroeconomic and geopolitical landscape, the company is poised to capitalize on industry opportunities with its diversified portfolio.